An Assessment of the Cost-Utility of Therapy for Psoriasis

Figures & data

Table 1 Analysis

	Before	After	Change (%)	P value
EQ5D	0.78	0.87	11.5	0.007
PASI	11.08	7.20	−35.0	<0.001
SAPASI	15.73	11.61	−26.2	0.04
DLQI	9.39	5.61	−40.2	<0.001
VAS	67.65	73.16	8.2	0.001
BSA	12.44	9.90	−20.4	<0.001

Abbreviations: BSA, body surface area; DLQI, Dermatology Life Quality Index; EQ5D, European QoL 5 Dimension survey; PASI, psoriasis area and severity index SAPASI, self-assessed psoriasis area and severity index; VAS, visual analog scale.

Table 2 Incremental cost-utility of a PASI 35 at different annual costs of therapy

Annual Cost of Therapy	CUA
$ 6,000.00	$ 8,925.08
$ 12,000.00	$ 17,850.16
$ 18,000.00	$ 26,775.24
$ 24,000.00	$ 35,700.33
$ 30,000.00	$ 44,625.41
$ 34,000.00	$ 50,575.46

Abbreviations: CUA, cost-utility analysis; PASI, psoriasis area and severity index.

Table 3 Comparisons across disease – Health State Utility (Ubel et al 2003)

Disease	Utility Score
CABG for coronary artery disease	0.84
Medical subgroup refusing CABG for Coronary Artery Disease	0.74
Psoriasis (PASI 35)	0.78
Medical management for Coronary Artery Disease	0.61

Abbreviations: CABG, coronary artery bypass graft; PASI, psoriasis area and severity index.

UbelPAHirthRAChernewMEWhat is the price of life and why doesn’t it increase at the rate of inflationArch Intern Med200316316374112885677

 PubMed Web of Science ®Google Scholar